Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group.

Blood
Sanne NoortC Michel Zwaan

Abstract

To study the prognostic relevance of rare genetic aberrations in acute myeloid leukemia (AML), such as t(16;21), international collaboration is required. Two different types of t(16;21) translocations can be distinguished: t(16;21)(p11;q22), resulting in the FUS-ERG fusion gene; and t(16;21)(q24;q22), resulting in RUNX1-core binding factor (CBFA2T3). We collected data on clinical and biological characteristics of 54 pediatric AML cases with t(16;21) rearrangements from 14 international collaborative study groups participating in the international Berlin-Frankfurt-Münster (I-BFM) AML study group. The AML-BFM cohort diagnosed between 1997 and 2013 was used as a reference cohort. RUNX1-CBFA2T3 (n = 23) had significantly lower median white blood cell count (12.5 × 109/L, P = .03) compared with the reference cohort. FUS-ERG rearranged AML (n = 31) had no predominant French-American-British (FAB) type, whereas 76% of RUNX1-CBFA2T3 had an M1/M2 FAB type (M1, M2), significantly different from the reference cohort (P = .004). Four-year event-free survival (EFS) of patients with FUS-ERG was 7% (standard error [SE] = 5%), significantly lower compared with the reference cohort (51%, SE = 1%, P < .001). Four-year EFS of RUNX1-CBFA2T3 was 77...Continue Reading

References

Jul 1, 1989·Cancer Genetics and Cytogenetics·S C RaimondiD L Williams
Dec 1, 1994·Genes, Chromosomes & Cancer·I PanagopoulosF Mitelman
Apr 1, 1996·Hematology and Cell Therapy·R BergerP Jonveaux
Jul 3, 2002·Nature Reviews. Cancer·Nancy A Speck, D Gary Gilliland
May 9, 2003·Lifetime Data Analysis·Ross L Prentice, John D Kalbfleisch
May 25, 2004·Oncogene·Marella F T R de Bruijn, Nancy A Speck
Apr 18, 2006·Cancer Genetics and Cytogenetics·Eric JeandidierUNKNOWN Groupe Français de Cytogénétique Hématologique (GFCH)
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN MRD-AML-BFM Study GroupDirk Reinhardt
Nov 28, 2006·Leukemia Research·Andrea ZatkovaPeter Valent
Feb 21, 2008·Acta Haematologica·Christie L Boils, Anwar N Mohamed
Jul 29, 2008·Cancer Genetics and Cytogenetics·Etienne De BraekeleerMarc De Braekeleer
Dec 8, 2009·Cancer Genetics and Cytogenetics·Il Joong ParkSung Ran Cho
Feb 2, 2010·Hematology/oncology Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Nov 9, 2010·Leukemia & Lymphoma·Anastasia AthanasiadouAchilles Anagnostopoulos
Mar 10, 2012·International Journal of Hematology·Nozomu KawashimaKoji Kato
Jan 5, 2014·British Journal of Haematology·Bruno C MedeirosFrederick R Appelbaum
Aug 4, 2015·Journal of Clinical Medicine·Jasmijn D E de RooijMarry van den Heuvel-Eibrink
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Michel ZwaanGertjan J L Kaspers
Sep 24, 2015·PloS One·Chih-Hao HsuSoheil Meshinchi
Oct 28, 2016·Paediatric Drugs·Jeffrey E Rubnitz
Jan 11, 2018·Journal of Hematology & Oncology·Jinghua WangPenghui Zhou
Feb 22, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Olivia CampagneDonald E Mager

❮ Previous
Next ❯

Citations

Aug 2, 2019·American Journal of Clinical Pathology·Marian H HarrisMagdalena Czader
Aug 20, 2019·Expert Review of Hematology·Anette Lodvir HemsingHåkon Reikvam
Dec 15, 2020·American Journal of Clinical Pathology·Rebecca L KingHarneet Hara
Apr 13, 2021·Pediatric Blood & Cancer·Grace EganJohann Hitzler
Jul 3, 2021·Genes·Julie QuessadaMarina Lafage-Pochitaloff

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.